SCHEMBL3577396

SCHEMBL3577396

Nc1c(Cl)cc(Cl)c(F)c1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.38
KEAP1 Q14145 2/20 0.37
NFE2L2 Q16236 1/20 0.37
DAO P14920 1/20 0.36
CA1 P00915 3/20 0.36
CA2 P00918 3/20 0.36
CA9 Q16790 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 2/20 0.36
ALPL P05186 1/20 0.36
CA12 O43570 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA13 Q8N1Q1 1/20 0.35
CISD1 Q9NZ45 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8377346 0.84 DPP4 (0.44) DPP4KEAP1NFE2L2DAOCA1
SCHEMBL31490367 0.79 GAA (0.39) DPP4KEAP1NFE2L2DAOALDH1A1
SCHEMBL31148735 0.77 GAA (0.35) DPP4KEAP1CA1CA2CA9
SCHEMBL10495775 0.77 CYP3A4 (0.39) DPP4DAOCA1CA2CA9
SCHEMBL28411843 0.74 CES2 (0.46) DPP4KEAP1NFE2L2CA1CA2
SCHEMBL2127072 0.73 DPP4 (0.45) DPP4ALDH1A1POLBKDM4EHSD17B10
SCHEMBL23496803 0.73 KEAP1 (0.41) KEAP1NFE2L2DAOCA1CA2
SCHEMBL28883701 0.73 ALDH1A1 (0.58) CA1CA2CA9ALDH1A1CA12
SCHEMBL25234282 0.73 GAA (0.35) DPP4KEAP1CA1CA2CA9
SCHEMBL30816046 0.73 POLB (0.41) CA1CA2CA9CA12CA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110835330-A Preparation method of substituted pyrazole amide compound with insecticidal activity 海利尔药业集团股份有限公司 2020-02-25 CN disclosed
EP-1984340-B1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2012-06-27 EP disclosed
US-7678818-B2 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1984340-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-10-29 EP disclosed
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds HOFFMANN-LA ROCHE INC. 2007-09-20 US disclosed
WO-2007090752-A1 ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070219261-A1 Anthranilamide and 2-amino-heteroarene-carboxamide compounds AADAT, AAAS, AADAC DPP4 2352/4885KEAP1 4197/4885NFE2L2 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.